Randox, Crumlin, UK, offers testing solutions for a range of cytokines, cytokine receptors, and growth factors designed to assist with covid-19 risk stratification and monitoring of treatment efficacy and recovery. The company’s biochip technology enables the detection of up to 12 cytokines and growth factors simultaneously from a single patient sample.
Cytokine storms are a common complication of SARS-CoV-2 infection, triggering viral sepsis, where viral replication and excessive, uncontrolled systemic inflammation may lead to pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, multiple organ failure, secondary bacterial pneumonia, and potentially death.
Randox’s comprehensive test menu includes 26 cytokines, cytokine receptors, and growth factors.
For more information, visit Randox.